Imiquimod for superficial and in situ skin malignancy

Drug and Therapeutics Bulletin

Volumn 47, Issue 10, 2009, Pages 113-116

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; PLACEBO; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT;

APPLICATION SITE BLEEDING; APPLICATION SITE BURNING; APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; APPLICATION SITE INFLAMMATION; APPLICATION SITE PAIN; APPLICATION SITE PARESTHESIA; APPLICATION SITE PRURITUS; APPLICATION SITE RASH; BACKACHE; BASAL CELL CARCINOMA; BOWEN DISEASE; CANCER RADIOTHERAPY; CANCER RISK; CARCINOMA IN SITU; CAUTERIZATION; CLINICAL FEATURE; CLINICAL TRIAL; CRYOSURGERY; CURETTAGE; DRUG COST; DRUG INDICATION; ERYTHEMA MULTIFORME; FLU LIKE SYNDROME; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; MALIGNANT LENTIGO; NAUSEA; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SKIN LUPUS ERYTHEMATOSUS; STEVENS JOHNSON SYNDROME; SUPERFICIAL CANCER; TREATMENT PLANNING; UNITED KINGDOM; XEROSTOMIA; ADULT; RANDOMIZED CONTROLLED TRIAL; SKIN TUMOR;

ADULT; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; BOWEN'S DISEASE; CARCINOMA, BASAL CELL; HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS;

EID: 77649214882     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2009.09.0040     Document Type: Review

References (26)

1. Aldara 5% cream. Summary of product characteristics, EU. Laboratoires 3M Santé, September 2003.
2. Cotter MA et al. Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg 2008; 34: 147-51.
3. Wagstaff AJ, Perry CM. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. Drugs 2007; 67: 2187-210.
4. Bath-Hextall F et al. Trends in incidence of skin basal cell carcinoma. Additional evidence from a UK primary care database study. Int J Cancer 2007; 121: 2105-8.
5. Roewert-Huber J et al. Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol 2007; 157 (suppl 2): 47-51.
6. Bath-Hextall F et al. Interventions for basal cell carcinoma of the skin. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD003412. DOI: 10.1002/14651858.CD003412.pub2. [Last assessed as up-to-date: 8 November 2006.]
7. Telfer NR et al. Guidelines for the management of basal cell carcinoma. Br J Dematol 2008; 159: 35-48.
8. So, what exactly is a cytokine? DTB 2009; 47: 89-91.
9. Gollnick H et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol 2005; 15: 374-81.
10. Gollnick H et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term followup study in Europe. Eur J Dermatol 2008; 18: 677-82.
11. Quirk C et al. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. Australas J Dermatol 2006; 47: 258-65.
12. Silverman MK et al. Recurrence rates of treated basal cell carcinomas. Part 1: Overview. J Dermatol Surg Oncol 1991; 17: 713-8.
13. Marks R et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44: 807-13.
14. Sterry W et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002; 147: 1227-36.
15. Geisse JK et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002; 47: 390-8.
16. Geisse J et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50: 722-33.
17. Schulze HJ et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 2005; 152: 939-47.
18. Scottish Medicines Consortium, 2005. Imiquimod 5% cream (Aldara) [online]. Available: http://www.scottishmedicines.org.uk/smc/files/ imiquimod%20ream%20(Aldara)%20(167-05).pdf [Accessed 22 September 2009].
19. Vanaclocha F et al. Cost-effectiveness of treatment of superficial basal cell carcinoma: surgical excision vs. imiquimod 5% cream. Br J Dermatol 2007; 156: 769-71.
20. National Institute for Health and Clinical Excellence, 2006. Guidance on cancer services. Improving outcomes for people with skin tumours including melanoma. The manual [online]. Available: http://www.nice.org.uk/nicemedia/ pdf/CSG-Skin-Manual.pdf [Accessed 22 September 2009].
21. Morton CA et al. Guidelines for topical photodynamic therapy: update. Br J Dermatol 2008; 159: 1245-66.
22. Patel GK et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebocontrolled trial. J Am Acad Dermatol 2006; 54: 1025-32.
23. Rajpar SF, Marsden JR. Imiquimod in the treatment of lentigo maligna. Br J Dermatol 2006; 155: 653-6.
24. Cox NH et al. Guidelines for management of Bowen's disease: 2006 update. Br J Dermatol 2007; 156: 11-21.
25. Roberts DLL et al. U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol 2002; 146: 7-17.
26. Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical practice guidelines for the management of melanoma in Australia and New Zealand. Wellington: New Zealand Guidelines Group, 2008.